Zydus Cadila gets final USFDA nod for drug to treat High BP

Macitentan is used to manage the symptoms of pulmonary arterial hypertension


Last Updated on April 9, 2021 by The Health Master

Zydus Cadila has received final approval from the USFDA to market Macitentan Tablets, 10 mg (US RLD: Opsumit Tablets).

Macitentan is used to manage the symptoms of pulmonary arterial hypertension. Macitentan is in a class of medications called endothelin receptor antagonists.

To read more about Hypertension, click here

It works by stopping the action of endothelin, a natural substance that causes blood vessels to narrow and prevents normal blood flow in people who have Pulmonary Arterial Hypertension.

Medicine Tablets
Picture: Unsolash

According to the USFDA letter, Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Macitentan Tablets, 10 mg.

Therefore, with this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Macitentan Tablets, 10 mg.

The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Also read:

Dr Reddy’s launch generic Sapropterin Dihydrochloride Powder for Oral Solution in…

Camber Pharma Launches Generic Succinylcholine Chloride Inj

Aleor gets USFDA nod for drug for cutaneous candidiasis treatment

Zealand Pharma got USFDA nod for severe Hypoglycemia drug

Glenmark gets USFDA nod for Chlorpromazine HCL tablets

Glenmark gets USFDA nod for Diltiazem HCL ER capsules

Subscribe for daily free updates


Enter your email address:

Delivered by FeedBurner